A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021.

Kayki-Mutlu, Gizem; Aksoyalp, Zinnet Sevval; Wojnowski, Leszek; Michel, Martin C

Kayki-Mutlu, Gizem; Aksoyalp, Zinnet Sevval; Wojnowski, Leszek; Michel, Martin C.

Afiliação

Kayki-Mutlu G; Department of Pharmacology, Faculty of Pharmacy, Ankara University, Ankara, Turkey.
Aksoyalp ZS; Department of Pharmacology, Faculty of Pharmacy, Izmir Katip Celebi University, Izmir, Turkey.
Wojnowski L; Department of Pharmacology, University Medical Center, Johannes Gutenberg University, Langenbeckstr. 1, 55118, Mainz, Germany.
Michel MC; Department of Pharmacology, University Medical Center, Johannes Gutenberg University, Langenbeckstr. 1, 55118, Mainz, Germany. marmiche@uni-mainz.de.

Naunyn Schmiedebergs Arch Pharmacol ; 395(8): 867-885, 2022 08.

Article em En | MEDLINE | ID: mdl-35543739

Assuntos

Tratamento Farmacológico da COVID-19; Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos; Aprovação de Drogas; Humanos; Pandemias; Estados Unidos; United States Food and Drug Administration

Palavras-chave

FDA; First-in-class; First-in-indication; New drugs; Next-in-class

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Tratamento Farmacológico da COVID-19 Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google